|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Fedewa SA, Miller KD,
Goding-Sauer A, Pinheiro PS, Martinez-Tyson D and Jemal A: Cancer
statistics for Hispanics/Latinos, 2015. CA Cancer J Clin.
65:457–480. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mizuno K, Mataki H, Seki N, Kumamoto T,
Kamikawaji K and Inoue H: MicroRNAs in non-small cell lung cancer
and idiopathic pulmonary fibrosis. J Hum Genet. 62:57–65. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yu T, Li J, Yan M, Liu L, Lin H, Zhao F,
Sun L, Zhang Y, Cui Y, Zhang F, et al: MicroRNA-193a-3p and −5p
suppress the metastasis of human non-small-cell lung cancer by
downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway.
Oncogene. 34:413–423. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xue J, Chi Y, Chen Y, Huang S, Ye X, Niu
J, Wang W, Pfeffer LM, Shao ZM, Wu ZH and Wu J: MiRNA-621
sensitizes breast cancer to chemotherapy by suppressing FBXO11 and
enhancing p53 activity. Oncogene. 35:448–458. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 9:8522017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shen B, Yu S, Zhang Y, Yuan Y, Li X, Zhong
J and Feng J: miR-590-5p regulates gastric cancer cell growth and
chemosensitivity through RECK and the AKT/ERK pathway. Onco Targets
Ther. 9:6009–6019. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li J, Wu H, Li W, Yin L, Guo S, Xu X,
Ouyang Y, Zhao Z, Liu S, Tian Y, et al: Downregulated miR-506
expression facilitates pancreatic cancer progression and
chemoresistance via SPHK1/Akt/NF-κB signaling. Oncogene.
35:5501–5514. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ai J, Huang H, Lv X, Tang Z, Chen M, Chen
T, Duan W, Sun H, Li Q, Tan R, et al: FLNA and PGK1 are two
potential markers for progression in hepatocellular carcinoma. Cell
Physiol Biochem. 27:207–216. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mueller LN, Brusniak MY, Mani DR and
Aebersold R: An assessment of software solutions for the analysis
of mass spectrometry based quantitative proteomics data. J Proteome
Res. 7:51–61. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lin HC, Zhang FL, Geng Q, Yu T, Cui YQ,
Liu XH, Li J, Yan MX, Liu L, He XH, et al: Quantitative proteomic
analysis identifies CPNE3 as a novel metastasis-promoting gene in
NSCLC. J Proteome Res. 12:3423–3433. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kaller M, Liffers ST, Oeljeklaus S,
Kuhlmann K, Röh S, Hoffmann R, Warscheid B and Hermeking H:
Genome-wide characterization of miR-34a induced changes in protein
and mRNA expression by a combined pulsed SILAC and microarray
analysis. Mol Cell Proteomics. 10:M111.0104622011.doi:
10.1074/mcp.M111.010462. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Baek D, Villen J, Shin C, Camargo FD, Gygi
SP and Bartel DP: The impact of microRNAs on protein output.
Nature. 455:64–71. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Litholdo CG Jr, Parker BL, Eamens AL,
Larsen MR, Cordwell SJ and Waterhouse PM: Proteomic identification
of putative microRNA394 target genes in arabidopsis thaliana
identifies major latex protein family members critical for normal
development. Mol Cell Proteomics. 15:2033–2047. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li J, Yu T, Cao J, Liu L, Liu Y, Kong HW,
Zhu MX, Lin HC, Chu DD, Yao M and Yan MX: MicroRNA-148a suppresses
invasion and metastasis of human non-small-cell lung cancer. Cell
Physiol Biochem. 37:1847–1856. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Joshi P, Jeon YJ, Lagana A, Middleton J,
Secchiero P, Garofalo M and Croce CM: MicroRNA-148a reduces
tumorigenesis and increases TRAIL-induced apoptosis in NSCLC. Proc
Natl Acad Sci USA. 112:8650–8655. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu A, Xia J, Zuo J, Jin S, Zhou H, Yao L,
Huang H and Han Z: MicroRNA-148a is silenced by hypermethylation
and interacts with DNA methyltransferase 1 in gastric cancer. Med
Oncol. 29:2701–2709. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang SL and Liu L: MicroRNA-148a inhibits
hepatocellular carcinoma cell invasion by targeting
sphingosine-1-phosphate receptor 1. Exp Ther Med. 9:579–584. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang R, Li M, Zang W, Chen X, Wang Y, Li
P, Du Y, Zhao G and Li L: miR-148a regulates the growth and
apoptosis in pancreatic cancer by targeting CCKBR and Bcl-2. Tumour
Biol. 35:837–844. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jiang Q, He M, Ma MT, Wu HZ, Yu ZJ, Guan
S, Jiang LY, Wang Y, Zheng DD, Jin F and Wei MJ: MicroRNA-148a
inhibits breast cancer migration and invasion by directly targeting
WNT-1. Oncol Rep. 35:1425–1432. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sakamoto N, Naito Y, Oue N, Sentani K,
Uraoka N, Oo Zarni H, Yanagihara K, Aoyagi K, Sasaki H and Yasui W:
MicroRNA-148a is downregulated in gastric cancer, targets MMP7, and
indicates tumor invasiveness and poor prognosis. Cancer Sci.
105:236–243. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yi WR, Li ZH, Qi BW, Ernest ME, Hu X and
Yu AX: Downregulation of IDH2 exacerbates the malignant progression
of osteosarcoma cells via increased NF-κB and MMP-9 activation.
Oncol Rep. 35:2277–2285. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Samanta D, Park Y, Andrabi SA, Shelton LM,
Gilkes DM and Semenza GL: PHGDH expression is required for
mitochondrial redox homeostasis, breast cancer stem cell
maintenance and lung metastasis. Cancer Res. 76:4430–4442. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhu QS, Rosenblatt K, Huang KL, Lahat G,
Brobey R, Bolshakov S, Nguyen T, Ding Z, Belousov R, Bill K, et al:
Vimentin is a novel AKT1 target mediating motility and invasion.
Oncogene. 30:457–470. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen CL, Chung T, Wu CC, Ng KF, Yu JS,
Tsai CH, Chang YS, Liang Y, Tsui KH and Chen YT: Comparative tissue
proteomics of microdissected specimens reveals novel candidate
biomarkers of bladder cancer. Mol Cell Proteomics. 14:2466–2478.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gao Y, Li G, Sun L, He Y, Li X, Sun Z,
Wang J, Jiang Y and Shi J: ACTN4 and the pathways associated with
cell motility and adhesion contribute to the process of lung cancer
metastasis to the brain. BMC Cancer. 15:2772015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou W, Fan MY, Wei YX, Huang S, Chen JY
and Liu P: The expression of MYH9 in osteosarcoma and its effect on
the migration and invasion abilities of tumor cell. Asian Pac J
Trop Med. 9:597–600. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Qin Q, Wei F, Zhang J and Li B: miR-134
suppresses the migration and invasion of non-small cell lung cancer
by targeting ITGB1. Oncol Rep. 37:823–830. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang XM, Li J, Yan MX, Liu L, Jia DS, Geng
Q, Lin HC, He XH, Li JJ and Yao M: Integrative analyses identify
osteopontin, LAMB3 and ITGB1 as critical pro-metastatic genes for
lung cancer. PLoS One. 8:e557142013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang H, Wang Y, Xu T, Li C, Wu J, He Q,
Wang G, Ding C, Liu K, Tang H and Ji F: Increased expression of
microRNA-148a in osteosarcoma promotes cancer cell growth by
targeting PTEN. Oncol Lett. 12:3208–3214. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lombard AP, Mooso BA, Libertini SJ, Lim
RM, Nakagawa RM, Vidallo KD, Costanzo NC, Ghosh PM and Mudryj M:
miR-148a dependent apoptosis of bladder cancer cells is mediated in
part by the epigenetic modifier DNMT1. Mol Carcinog. 55:757–767.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li J, Song Y, Wang Y, Luo J and Yu W:
MicroRNA-148a suppresses epithelial-to-mesenchymal transition by
targeting ROCK1 in non-small cell lung cancer cells. Mol Cell
Biochem. 380:277–282. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Simon-Assmann P, Orend G, Mammadova-Bach
E, Spenlé C and Lefebvre O: Role of laminins in physiological and
pathological angiogenesis. Int J Dev Biol. 55:455–465. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tanis T, Cincin ZB, Gokcen-Rohlig B,
Bireller ES, Ulusan M, Tanyel CR and Cakmakoglu B: The role of
components of the extracellular matrix and inflammation on oral
squamous cell carcinoma metastasis. Arch Oral Biol. 59:1155–1163.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yamamoto N, Kinoshita T, Nohata N, Itesako
T, Yoshino H, Enokida H, Nakagawa M, Shozu M and Seki N: Tumor
suppressive microRNA-218 inhibits cancer cell migration and
invasion by targeting focal adhesion pathways in cervical squamous
cell carcinoma. Int J Oncol. 42:1523–1532. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kinoshita T, Hanazawa T, Nohata N, Kikkawa
N, Enokida H, Yoshino H, Yamasaki T, Hidaka H, Nakagawa M, Okamoto
Y and Seki N: Tumor suppressive microRNA-218 inhibits cancer cell
migration and invasion through targeting laminin-332 in head and
neck squamous cell carcinoma. Oncotarget. 3:1386–1400. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tadokoro A, Kanaji N, Liu D, Yokomise H,
Haba R, Ishii T, Takagi T, Watanabe N, Kita N, Kadowaki N and
Bandoh S: Vimentin regulates invasiveness and is a poor prognostic
marker in non-small cell lung cancer. Anticancer Res. 36:1545–1551.
2016.PubMed/NCBI
|
|
44
|
Unterlass JE, Basle A, Blackburn TJ,
Tucker J, Cano C, Noble ME and Curtin NJ: Validating and enabling
phosphoglycerate dehydrogenase (PHGDH) as a target for
fragment-based drug discovery in PHGDH-amplified breast cancer.
Oncotarget. 13139–13153. 2018.PubMed/NCBI
|
|
45
|
Xian Y, Zhang S, Wang X, Qin J, Wang W and
Wu H: Phosphoglycerate dehydrogenase is a novel predictor for poor
prognosis in gastric cancer. Onco Targets Ther. 9:5553–5560. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shao H, Wang JH, Pollak MR and Wells A:
α-actinin-4 is essential for maintaining the spreading, motility
and contractility of fibroblasts. PLoS One. 5:e139212010.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tian GY, Zang SF, Wang L, Luo Y, Shi JP
and Lou GQ: Isocitrate dehydrogenase 2 suppresses the invasion of
hepatocellular carcinoma cells via matrix metalloproteinase 9. Cell
Physiol Biochem. 37:2405–2414. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lv Q, Xing S, Li Z, Li J, Gong P, Xu X,
Chang L, Jin X, Gao F, Li W, et al: Altered expression levels of
IDH2 are involved in the development of colon cancer. Exp Ther Med.
4:801–806. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tomlinson IP, Alam NA, Rowan AJ, Barclay
E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, et
al: Germline mutations in FH predispose to dominantly inherited
uterine fibroids, skin leiomyomata and papillary renal cell cancer.
Nat Genet. 30:406–410. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ming Z, Jiang M, Li W, Fan N, Deng W,
Zhong Y, Zhang Y, Zhang Q and Yang S: Bioinformatics analysis and
expression study of fumarate hydratase in lung cancer. Thorac
Cancer. 5:543–549. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cai XZ, Zeng WQ, Xiang Y, Liu Y, Zhang HM,
Li H, She S, Yang M, Xia K and Peng SF: iTRAQ-based quantitative
proteomic analysis of nasopharyngeal carcinoma. J Cell Biochem.
116:1431–1441. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Choi SH, Nam JK, Kim BY, Jang J, Jin YB,
Lee HJ, Park S, Ji YH, Cho J and Lee YJ: HSPB1 inhibits the
endothelial-to-mesenchymal transition to suppress pulmonary
fibrosis and lung tumorigenesis. Cancer Res. 76:1019–1030. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Potenta S, Zeisberg E and Kalluri R: The
role of endothelial-to-mesenchymal transition in cancer
progression. Br J Cancer. 99:1375–1379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lin F, Wang N and Zhang TC: The role of
end othelial-mesenchymal transition in development and pathological
process. IUBMB Life. 64:717–723. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Augsten M: Cancer-associated fibroblasts
as another polarized cell type of the tumor microenvironment. Front
Oncol. 4:622014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zeisberg EM, Potenta S, Xie L, Zeisberg M
and Kalluri R: Discovery of endothelial-to-mesenchymal transition
as a source for carcinoma-associated fibroblasts. Cancer Res.
67:10123–10128. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Gasperini P, Espigol-Frigole G, McCormick
PJ, Salvucci O, Maric D, Uldrick TS, Polizzotto MN, Yarchoan R and
Tosato G: Kaposi sarcoma herpesvirus promotes
endothelial-to-mesenchymal transition through notch-dependent
signaling. Cancer Res. 72:1157–1169. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Krizbai IA, Gasparics Á, Nagyőszi P,
Fazakas C, Molnár J, Wilhelm I, Bencs R, Rosivall L and Sebe A:
Endothelial-mesenchymal transition of brain endothelial cells:
Possible role during metastatic extravasation. PLoS One.
10:e01238452015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
van Meeteren LA and ten Dijke P:
Regulation of endothelial cell plasticity by TGF-β. Cell Tissue
Res. 347:177–186. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Cui J, Quan M, Jiang W, Hu H, Jiao F, Li
N, Jin Z and Wang L, Wang Y and Wang L: Suppressed expression of
LDHB promotes pancreatic cancer progression via inducing glycolytic
phenotype. Med Oncol. 32:1432015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Li C, Chen Y, Bai P, Wang J, Liu Z, Wang T
and Cai Q: LDHB may be a significant predictor of poor prognosis in
osteosarcoma. Am J Transl Res. 8:4831–4843. 2016.PubMed/NCBI
|
|
62
|
Wang J, Zhang X, Shi J, Cao P, Wan M,
Zhang Q, Wang Y, Kridel SJ, Liu W, Xu J, et al: Fatty acid synthase
is a primary target of miR-15a and miR-16-1 in breast cancer.
Oncotarget. 7:78566–78576. 2016.PubMed/NCBI
|
|
63
|
Cerne D, Zitnik IP and Sok M: Increased
fatty acid synthase activity in non-small cell lung cancer tissue
is a weaker predictor of shorter patient survival than increased
lipoprotein lipase activity. Arch Med Res. 41:405–409. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Tsai JY, Lee MJ, Chang Dah-Tsyr M and
Huang H: The effect of catalase on migration and invasion of lung
cancer cells by regulating the activities of cathepsin S, L and K.
Exp Cell Res. 323:28–40. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhang W and Xu J: DNA methyltransferases
and their roles in tumorigenesis. Biomark Res. 5:12017. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Xu Q, Jiang Y, Yin Y, Li Q, He J, Jing Y,
Qi YT, Xu Q, Li W, Lu B, et al: A regulatory circuit of
miR-148a/152 and DNMT1 in modulating cell transformation and
tumorangiogenesis through IGF-IR and IRS1. J Mol Cell Biol. 5:3–13.
2013. View Article : Google Scholar : PubMed/NCBI
|
